pharma · Chronic Lymphocytic Leukemia (CLL) · Relapsed/Refractory B-cell Malignancies · NRIX
Nurix Therapeutics
Nurix Therapeutics is a pharma organization headquartered in Brisbane, USA. It trades on NYSE under ticker NRIX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia (CLL), Relapsed/Refractory B-cell Mali
Brisbane, USA HQ
2012 Founded
350 Employees
Public company Type
NRIX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Founded
- 2012
- Employees
- 350
- Programs
- 9
- Drugs
- 4
- Patents
- 14
Drug Product De-TIL-0255
Phase 1 · mab · Platinum-resistant Ovarian Cancer
Drug Product De-TIL-0255 for Platinum-resistant Ovarian Cancer is a Phase 1 program (mab) at Nurix Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code NX-DeTIL-0255-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nurix Therapeutics
- Phase
- Phase 1
- Modality
- mab
- Indication
- Platinum-resistant Ovarian Cancer
- Status
- terminated
- Trials
- 1